

NOVARTIS AG  
Form 6-K  
July 19, 2007

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Report on Form 6-K dated July 17, 2007**

**(Commission File No. 1-15024)**

*This Report on Form 6-K shall be incorporated by reference in our Registration Statements on Form F-3 as filed with the Commission on May 11, 2001 (File No. 333-60712) and our Registration Statements on Form S-8 as filed with the Commission on September 5, 2006 (File No. 333-137112) and on October 1, 2004 (File No. 333-119475), in each case to the extent not superseded by documents or reports subsequently filed by us under the Securities Act of 1933 or the Securities Exchange Act of 1934, in each case as amended*

---

**Novartis AG**

(Name of Registrant)

**Lichtstrasse 35**

**4056 Basel**

**Switzerland**

Edgar Filing: NOVARTIS AG - Form 6-K

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F:**  **Form 40-F:**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes:  **No:**

-

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes:  **No:**

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes:  **No:**

Enclosure: **Novartis AG Announces Results for the First Quarter of 2007**

---

**Novartis International AG**  
Novartis Global  
Communications  
CH-4002 Basel  
Switzerland  
<http://www.novartis.com>

**QUARTERLY REPORT      RAPPORT TRIMESTRIEL      QUARTALSBERICHT**

**Novartis delivers strong performance in first half of 2007**

*Group first-half net sales advance 14% (+11% in local currencies) to USD 19.9 billion on solid contributions from all divisions*

*Net income up 14% to USD 4.2 billion and EPS rises 14% to USD 1.78 per share*

*Operating income from continuing operations up 13% and net income from continuing operations advances 17%*

*New pharmaceutical brands – particularly Tekturna, Lucentis, Exjade and Exforge – performing dynamically; seven major regulatory approvals achieved to date in 2007*

*Proceeds from non-core divestments to fund targeted acquisitions and repurchase of up to approximately USD 4 billion of Novartis shares by February 2008*

*Outlook maintained for record 2007 operating and net income for continuing operations; Group net sales growth revised to mid-single-digits in local currencies*

*Pharmaceuticals net sales growth expected to slow in second half of 2007, mainly from US generic competition for Lotrel and Lamisil and the Zelnorm suspension*

**Key Group figures**

## First half

	H1 2007		H1 2006		% Change	
	USD m	% of net sales	USD m	% of net sales	USD	lc
<b>Net sales</b>	<b>19 941</b>		17 483		14	11
<b>Operating income</b>	<b>4 669</b>	23.4	4 262	24.4	10	
<b>Net income</b>	<b>4 187</b>	21.0	3 669	21.0	14	
<b>Basic earnings per share/ADS</b>	<b>USD 1.78</b>		USD 1.56		14	

## Second quarter

	Q2 2007		Q2 2006		% Change	
	USD m	% of net sales	USD m	% of net sales	USD	lc
<b>Net sales</b>	<b>10 122</b>		9 182		10	7
<b>Operating income</b>	<b>2 216</b>	21.9	2 060	22.4	8	
<b>Net income</b>	<b>2 016</b>	19.9	1 713	18.7	18	
<b>Basic earnings per share/ADS</b>	<b>USD 0.86</b>		USD 0.73		18	

All product names appearing in italics are trademarks owned by or licensed to Novartis Group Companies

---

**Basel, July 17, 2007** Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: *All areas of our strategic healthcare portfolio performed well in the first half of 2007 despite some setbacks in the Pharmaceuticals Division. Continuing our focus on innovation, we have already achieved seven major regulatory approvals this year and more are expected in the second half. Many of these new products are meeting high expectations, while our leading brands Diovan and Gleevec/Glivec keep growing dynamically. Sandoz and Vaccines and Diagnostics again delivered strong growth. Our complementary healthcare businesses are positioning us well to fulfill a broad spectrum of patient needs and meet the challenges of an increasingly volatile sector.*

### First half 2007

#### Net sales

	H1 2007	H1 2006	% Change	
	USD m	USD m	USD	lc
<b>Pharmaceuticals</b>	<b>11 988</b>	10 751	12	9
<b>Vaccines and Diagnostics</b>	<b>482</b>	127		
<b>Sandoz</b>	<b>3 415</b>	2 881	19	13
<b>Consumer Health continuing operations</b>	<b>2 643</b>	2 415	9	6
<b>Net sales from continuing operations</b>	<b>18 528</b>	16 174	15	11
Consumer Health discontinuing operations <sup>(1)</sup>	1 413	1 309	8	7
<b>Total</b>	<b>19 941</b>	17 483	14	11

(1) Discontinuing operations include Medical Nutrition and Gerber in 2007 and Medical Nutrition, Gerber and Nutrition & Santé in 2006. The divestiture of Medical Nutrition was completed on July 1, 2007.

#### **Group net sales rise 14% (+11% lc) to USD 19.9 billion**

Dynamic performances from Sandoz and Vaccines and Diagnostics as well as solid growth in Pharmaceuticals and Consumer Health supported the double-digit expansion. Higher sales volumes represented seven percentage points of growth and acquisitions three percentage points, while currency translation had a positive impact of three points and net price changes added one point.

#### **Pharmaceuticals net sales advance 12% (+9% lc) to USD 12.0 billion**

Ongoing strong growth in the top-selling brands *Diovan* (USD 2.4 billion, +19% lc) and *Gleevec/Glivec* (USD 1.4 billion, +14% lc) both No. 1 in their segments underpinned the performance. Recently launched brands such as *Exforge*, *Exjade*, *Lucentis*, *Prexige* and *Tektural/Rasilez* continued growing rapidly. US net sales rose 5%, as growth in several brands helped offset the impact of the *Zelnorm* suspension in March and generic competition for *Lotrel* starting in May.

**Vaccines and Diagnostics net sales of USD 482 million**

Key drivers were growth in deliveries of components for use in combination pediatric vaccines as well as vaccines for tick-borne encephalitis. Diagnostics products, mainly used for blood testing, delivered further double-digit growth. The year-ago period included net sales for only two months following the April 2006 acquisition. Net sales on a comparable basis were up 45% over the 2006 period recorded by Chiron.

**Sandoz net sales expand 19% (+13% lc) to USD 3.4 billion**

Recent US product launches, in particular for difficult-to-make products, underpinned the dynamic performance as this region accounted for 28% of total net sales. Improving positions in markets such as Eastern Europe, Scandinavia, Canada and Latin America further supported double-digit growth.

**Consumer Health continuing operations net sales up 9% (+6% 1c) to USD 2.6 billion**

OTC provided strong growth ahead of the market thanks to strategic brands and expansion in emerging markets, while Animal Health benefited from further expansion in key markets.

**Operating income**

	H1 2007		H1 2006		Change
	USD m	% of net sales	USD m	% of net sales	In %
<b>Pharmaceuticals</b>	<b>3 620</b>	30.2	3 303	30.7	10
<b>Vaccines and Diagnostics</b>	<b>7</b>	1.5	-38		
<b>Sandoz</b>	<b>561</b>	16.4	445	15.4	26
<b>Consumer Health continuing operations</b>	<b>483</b>	18.3	446	18.5	8
Corporate income & expense, net	-239		-218		10
<b>Operating income from continuing operations</b>	<b>4 432</b>	23.9	3 938	24.3	13
Consumer Health discontinuing operations <sup>(1)</sup>	237	16.8	324	24.8	-27
<b>Total</b>	<b>4 669</b>	23.4	4 262	24.4	10

(1) Discontinuing operations include Medical Nutrition and Gerber in 2007 and Medical Nutrition, Gerber and Nutrition & Santé in 2006. The 2006 results include a pre-tax divestment gain of USD 129 million from the sale of Nutrition & Santé. The divestiture of Medical Nutrition was completed on July 1, 2007.

**Group operating income rises 10% to USD 4.7 billion**

Operating income rose slower than net sales as the year-ago period included a one-time gain from the sale of Nutrition & Santé. Operating income from continuing operations was up 13% due to strong underlying contributions from all divisions, particularly Sandoz and Pharmaceuticals.

**Pharmaceuticals operating income up 10% to USD 3.6 billion**

The decline in operating margin to 30.2% reflected primarily the ongoing strong investments in new product launches as well as in trials for key late-stage development projects. R&D investments rose 26% and were 20.3% of net sales – an increase of 2.4 percentage points from the year-ago period mainly for major projects entering Phase III and IV trials (FTY720, QAB149, *Tekturna/Rasilez*, *Galvus*, RAD001, SOM230, AGO178 and ABF656). Marketing & Sales expenses rose to 31.4% of net sales, an increase of 0.7 percentage points from the year-ago period, to support new product launches including *Tekturna/Rasilez*, *Exforge*, *Prexige*, *Exjade* and *Lucentis*. Productivity gains partially offset the higher investments in development and new product launches. Other Expenses, net of Other Income were sharply reduced in the 2007 first half, primarily reflecting the reversal of a one-time USD 107 million pre-launch inventory provision for *Tekturna/Rasilez* following US approval in March 2007 and acquisition-related charges in 2006. Excluding exceptional items in both periods, operating income rose 7% and the operating margin was 29.9%.

**Vaccines and Diagnostics provides operating income of USD 7 million**

Underlying operating income of USD 160 million (before restructuring and acquisition-related amortization charges of USD 153 million) reflected the ongoing business expansion for non-influenza vaccines and steady growth in diagnostics. Reported operating income also included one-time contributions in the 2007 first half of USD 83 million from legal and other settlements.

**Sandoz operating income advances 26% to USD 561 million**

Volume growth from several new product launches, particularly in the US, underpinned the growth in operating income ahead of net sales. Productivity gains and better economies of scale in key markets more than offset ongoing investments in new product development and the negative



impact of regulatory changes in some markets. Focus on high-margin sales as well as strong productivity gains in the anti-infectives business also positively impacted profitability. The operating income margin improved by one percentage point to 16.4%.

### Consumer Health continuing operations operating income up 8% to USD 483 million

Operating income progressed well as significant investments were made in R&D and marketing initiatives for new product launches as well as ongoing geographic expansion in emerging markets and Japan.

### Second quarter 2007

#### Net sales

	Q2 2007	Q2 2006	% Change	
	USD m	USD m	USD	lc
<b>Pharmaceuticals</b>	<b>6 065</b>	5 699	6	4
<b>Vaccines and Diagnostics</b>	<b>251</b>	127		
<b>Sandoz</b>	<b>1 719</b>	1 450	19	13
<b>Consumer Health continuing operations</b>	<b>1 365</b>	1 232	11	7
<b>Net sales from continuing operations</b>	<b>9 400</b>	8 508	10	7
Consumer Health discontinuing operations <sup>(1)</sup>	722	674	7	5
<b>Total</b>	<b>10 122</b>	9 182	10	7

(1) Discontinuing operations include Medical Nutrition and Gerber in 2007 and Medical Nutrition, Gerber and Nutrition & Santé in 2006. The divestiture of Medical Nutrition was completed on July 1, 2007.

### Group net sales up 10% (+7% lc) to USD 10.1 billion

Outstanding performances from Sandoz, Vaccines and Diagnostics and Consumer Health helped offset lower sales in Pharmaceuticals in the US. Four percentage points of Group net sales growth came from higher sales volumes, while acquisitions added two points and net price changes one point. Currency translation had a positive impact of three points.

### Pharmaceuticals net sales rise 6% (+4% lc) to USD 6.1 billion

Europe, Latin America and emerging markets supported the overall performance, which was impacted by a 6% decline in the US after the suspension of *Zelnorm* and generic competition for *Lotrel*. Strong growth came from the top brands *Diovan* (USD 1.2 billion, +17% lc), *Gleevec/Glivec* (USD 747 million, +12% lc) and *Femara* (USD 231 million, +28% lc) as well as from new products such as *Exforge*, *Tektura/Rasilez*, *Prexige*, *Exjade* and *Lucentis*.

**Vaccines and Diagnostics net sales advance to USD 251 million**

The dynamic performance came mainly from higher deliveries of components for multivalent pediatric vaccines as well as for various non-influenza vaccines, including tick-borne encephalitis. Diagnostics benefited from geographic expansion outside the US. The 2006 period includes two months of net sales after the April 2006 acquisition. On a comparable basis, net sales were up 44% over the 2006 period recorded by Chiron.

**Sandoz net sales grow 19% (+13% 1c) to USD 1.7 billion**

Ongoing growth in the US, where net sales rose 27%, drove the division's double-digit expansion. New product launches in the US performed very well, including anti-infectives such as cefdinir (Omnicef<sup>®</sup>)<sup>(1)</sup> and an authorized generic version of *Lotrel*. Other markets – particularly Eastern Europe, India, Canada, Brazil, Australia and Turkey – showed strong growth based on new product launches and in some cases rising generic utilization rates.

---

(1) Omnicef<sup>®</sup> is a registered trademark of Abbott Laboratories

**Consumer Health continuing operations net sales up 11% (+7% lc) to USD 1.4 billion**

OTC generated solid growth from strategic brands, expansion in emerging markets, new product launches in Europe and the recent entry into Japan, the world's No. 2 OTC market. Animal Health also grew at a double-digit rate, while CIBA Vision net sales were higher mainly on improved availability of lens care products.

**Operating income**

	Q2 2007		Q2 2006		Change
	USD m	% of net sales	USD m	% of net sales	In %
<b>Pharmaceuticals</b>	<b>1 767</b>	29.1	1 677	29.4	5
<b>Vaccines and Diagnostics</b>	<b>-20</b>		-38		
<b>Sandoz</b>	<b>243</b>	14.1	207	14.3	17
<b>Consumer Health continuing operations</b>	<b>243</b>	17.8	216	17.5	13
Corporate income & expense, net	<b>-136</b>		-98		
<b>Operating income from continuing operations</b>	<b>2 097</b>	22.3	1 964	23.1	7
Consumer Health discontinuing operations <sup>(1)</sup>	119	16.5	96	14.2	24
<b>Total</b>	<b>2 216</b>	21.9	2 060	22.4	8

(1) Discontinuing operations include Medical Nutrition and Gerber in 2007 and Medical Nutrition, Gerber and Nutrition & Santé in 2006. The divestiture of Medical Nutrition was completed on July 1, 2007.

**Group operating income up 8% to USD 2.2 billion**

All divisions contributed to the improved operating income, particularly the double-digit expansion in Sandoz and Consumer Health that helped to compensate for lower growth in Pharmaceuticals.

**Pharmaceuticals operating income rises 5% to USD 1.8 billion**

Continued significant investments in Research & Development and Marketing & Sales led to a decline in the operating margin to 29.1% of net sales. R&D expenses rose to 20.0% of net sales, driven by major projects entering late-stage trials compared to the 2006 second quarter. Marketing & Sales expenses were up 11% and represented 32.3% of net sales, mainly due to investments in new products such as *Tekturna/Rasilez*, *Exforge*, *Prexige*, *Exjade* and *Lucentis*. Productivity gains helped to partially offset these investments. In addition, lower acquisition-related charges had a positive impact on Other Income & Expense. Excluding exceptional items in both periods, operating income fell 1%, while operating margin declined to 29.5% from 31.8% in the prior-year period.

**Vaccines and Diagnostics operating loss of USD 20 million**

Operating income was USD 55 million before restructuring and acquisition-related amortization charges of USD 75 million, which led to the reported operating loss. The relatively low underlying operating income contribution during the second quarter reflects the seasonal nature of this business.

**Sandoz operating income advances 17% to USD 243 million**

The double-digit growth reflected volume expansion from the recent wave of new product launches, particularly in the US and other key markets. Productivity gains, including lower production costs, more than offset new product investments and expansion plans in emerging markets.

**Consumer Health continuing operations operating income up 13% to USD 243 million**

Strong volume growth in net sales underpinned the improvement and supported investments in sales forces and marketing for new product launches and geographic expansion into new markets, mainly in Animal Health and OTC.

**Corporate**

**Income from associated companies**

Income from associated companies was USD 95 million in the second quarter compared to USD 1 million in the year-ago period, reflecting one-time charges in 2006 for the Chiron acquisition. The investment in Roche provided a contribution of USD 87 million, up from USD 72 million in the 2006 second quarter. In the first half, associated companies provided income of USD 192 million compared to USD 105 million in the year-ago period.

**Financial income, net**

Net financial income rose to USD 33 million in the second quarter, up from USD 4 million in the year-ago period and mainly reflecting the realization of gains from the sale of marketable securities and excellent currency management. For the first half, net financial income was USD 67 million, a 24% increase from the year-ago period.

**Group net income**

Group net income in the second quarter rose 18%, faster than operating income based on the beneficial impact of income from associated companies and a lower anticipated tax rate of 14.0% in the quarter compared to 17.0% in the year-ago period. For the first six months of 2007, Group net income rose 14%, also faster than operating income thanks to higher contributions from associated companies and the lower anticipated tax rate of 15.0%. The reduced tax rates for these periods mainly reflect the impact of deferred tax accounting effects on completing legal restructurings following the Chiron acquisition.

**Balance sheet**

The Group's equity rose to USD 43.7 billion at June 30, 2007, compared to USD 41.3 billion at December 31, 2006. First-half net income of USD 4.2 billion as well as actuarial gains from employee benefit plans of USD 1.2 billion and a contribution of USD 0.3 billion from share-based compensation and USD 0.3 billion in currency translation gains more than offset the dividend payment of USD 2.6 billion and share repurchases of USD 1.1 billion.

Total liquidity declined slightly to USD 7.5 billion from USD 8.0 billion at the end of 2006, while the debt/equity ratio improved to 0.17:1 compared to 0.18:1 at the end of 2006.

Novartis is one of the few non-financial services companies worldwide to have attained the highest credit ratings from Standard & Poor's, Moody's and Fitch, the three benchmark rating agencies. S&P has rated Novartis as AAA for long-term maturities and as A1+ for short-term

## Edgar Filing: NOVARTIS AG - Form 6-K

maturities. Moody's has rated the Group as Aaa and P1, respectively, while Fitch has rated Novartis as AAA for long-term maturities and as F1+ for short-term maturities.

### **Cash flow**

Cash flow from operating activities from continuing operations in the 2007 first half was USD 3.9 billion, up USD 0.3 billion from the year-ago period. Net cash used in financing activities was USD 3.3 billion, of which USD 2.6 billion was for the 2006 dividend payment, USD 1.0 billion

for the purchase of treasury shares offset by USD 0.3 billion in other net financing cash inflow. For continuing operations, free cash flow after dividends was USD 111 million in the first half, down from USD 604 million in the year-ago period due mainly to the increased dividend payment for 2006.

#### **Targeted investments to strengthen healthcare portfolio**

Novartis is strategically repositioning its activities to focus solely on healthcare, areas where the Group has expertise and synergies to better address the needs of patients, physicians and societies in a dynamically changing healthcare environment. These areas include innovative pharmaceuticals for human and animal health, vaccines and diagnostics, generics and consumer health products such as over-the-counter (OTC) brands.

Targeted acquisitions will be considered that strengthen this healthcare portfolio. Novartis and Intercell AG signed in July one of the industry's most innovative comprehensive alliances that broadens the Novartis vaccines portfolio. Novartis has gained access to over 10 Intercell projects in preclinical and early-stage development, including vaccines for prevention of hospital-acquired infections and other life-threatening diseases, in return for an upfront payment and equity investment totaling USD 364 million (EUR 270 million). Novartis will assume responsibility for Phase III development, manufacturing and commercialization for any Intercell projects chosen after Phase II trials.

Divestments of non-core businesses are on track to be finished in 2007. The sale of Medical Nutrition to Nestlé for USD 2.5 billion was completed on July 1, while the Gerber baby foods business sale to Nestlé for USD 5.5 billion is set to be completed in the second half.

#### **Repurchase of up to approximately USD 4 billion in Novartis shares**

Utilizing the Group's strong free cash flow and proceeds from divestitures, Novartis intends to complete the previously approved share repurchase programs and to buy back the remaining open amount of up to approximately USD 4 billion in shares by the next Annual General Meeting in February 2008. Shares worth USD 0.8 billion were already repurchased during the 2007 first half via a second trading line on the SWX Swiss Exchange.

#### **Group outlook**

##### **(For continuing operations, barring any unforeseen events)**

With one of the industry's most productive late-stage pipelines, Novartis has made significant progress during 2007 in launching new medicines after gaining important regulatory approvals. This intensive launch plan and strong growth prospects for the Group's strategic healthcare portfolio are expected to underpin mid-term growth through 2010 and beyond and position Novartis for further years of record results.

During the rest of 2007, the Pharmaceuticals Division's net sales will be negatively impacted by the suspension of *Zelnorm* and US generic competition for *Lotrel* and *Lamisil*. Annual net sales for these products in 2006 amounted to USD 2.5 billion. As a result, Novartis has revised its full year outlook to mid-single-digit growth in net sales for Group continuing operations and to low-single-digit growth in the Pharmaceuticals Division, both in local currencies.

## Edgar Filing: NOVARTIS AG - Form 6-K

The Pharmaceuticals Division will continue during 2007 to reallocate resources to support new product launches and accelerate productivity initiatives. Based on these initiatives, and also plans for continued strong performances from other divisions, Novartis reaffirms expectations for record operating and net income from continuing operations in 2007.



### Pharmaceuticals product performance update

*Note: All growth figures refer to year-to-date worldwide sales growth in local currencies*

Novartis has received seven major new regulatory approvals for pharmaceuticals in the US and Europe since the start of 2007, making significant progress in delivering a wave of new medicines – many with first-in-class status addressing significant medical needs.

These include the approval and launch of the high blood pressure medicine *Tekturna/Rasilez* in the US, with a launch in Europe anticipated soon. *Exforge* was launched in the US – three months ahead of schedule – and also in Europe. Others approved and launched in the first half were *Aclasta/Reclast* in the US for Paget's disease, the blindness therapy *Lucentis* in Europe and *Sebivo* in Europe and China for hepatitis B. *Exelon Patch* won US approval in July as the first skin patch therapy for Alzheimer's disease and Parkinson's disease dementia.

A review of the leading marketed pharmaceutical products follows:

*Diovan* (USD 2.4 billion, +19% lc) has become the world's No. 1 branded high blood pressure medicine thanks to its status as one of the fastest-growing medicines in its market segment. *Diovan* has the potential to become one of the industry's top five pharmaceuticals based on annual worldwide sales. A primary growth driver has been increasing awareness about the consequences of uncontrolled high blood pressure, including studies showing 70% of patients do not reach their treatment goals. All regions delivered strong performances, supported in particular by recently published results of the JIKEI heart study underscoring efficacy in reducing the risk of cardiovascular events, especially strokes. *Co-Diovan*, a single-tablet combination with a diuretic, grew dynamically in both the US and Europe.

*Gleevec/Glivec* (USD 1.4 billion, +14% lc), a targeted therapy used in patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) as well as other rare cancers, maintained strong growth thanks to improved survival rates for patients, expansion of the GIST market and use in newly-approved rare diseases. New competition had little impact on underlying demand. Data presented at the American Society of Clinical Oncology (ASCO) meeting showed one year of treatment with *Gleevec/Glivec* led to an 82% reduction in the risk of cancer returning in patients who underwent surgery for GIST tumors. These findings may lead to changes in clinical practice recommendations, and regulatory submissions are planned for 2008. Development of *Gleevec/Glivec* for use in an aggressive brain tumor known as glioblastoma multiforme was halted in the second quarter after study results showed no improvement in progression-free survival.

*Zometa* (USD 636 million, –1% lc), an intravenous bisphosphonate for patients with bone cancer, has been affected by overall slowing growth for this segment following price reductions in Europe and changes in prescribing that has reduced frequency of use in cancer patients. However, use in patients with lung and prostate cancers continues to rise. *Zometa* is now the leading infusional bisphosphonate in Japan after its launch just 15 months ago.

*Lotrel* (USD 594 million, 8% lc, only in US) was negatively impacted by the at risk launch of a generic copy by Teva Pharmaceuticals in May 2007 despite a valid US patent until 2017. Sandoz subsequently launched a generic version of this medicine, which is a fixed-dose combination therapy for high blood pressure. Novartis will continue to defend its intellectual property rights. A trial date has not been set for the ongoing lawsuit against Teva, which risks potentially significant damages if Novartis prevails.

*Sandostatin* (USD 491 million, +8% lc), for patients with acromegaly as well as treatment of patients with certain tumors, reported 14% worldwide growth for the long-acting-release *Sandostatin LAR* version that accounts for approximately 85% of net sales.

*Femara* (USD 439 million, +30% lc), a leading oral treatment for women with hormone-sensitive breast cancer, experienced further dynamic growth worldwide. Compelling clinical data shows that *Femara* is the first aromatase inhibitor when used as an initial therapy to demonstrate a significant reduction in the risk of breast cancer spreading to other parts of the body. Market share gains continue in early adjuvant treatment in women immediately following cancer surgery.

*Lamisil* (USD 432 million, -11% lc), an oral treatment for fungal nail infections, had lower net sales ahead of the entry of generic competition in the US, which began on July 2. Ongoing generic competition further eroded net sales in Europe.

*Trileptal* (USD 396 million, +11% lc), a treatment for epilepsy seizures, generated strong growth in key markets. Generic competition may emerge in the US during this year.

*Exelon* (USD 297 million, +17%), a treatment for mild to moderate forms of Alzheimer's disease dementia and dementia associated with Parkinson's disease, maintained its strong expansion in both the US and other key markets. *Exelon Patch* received US regulatory approval in early July. The constant 24-hour delivery of *Exelon*'s active ingredient through a skin patch showed equivalent efficacy at the target dose to the highest doses of capsules but with three times fewer reports of nausea or vomiting. The patch was preferred by over 70% of family members as it helps in the management of day-to-day patient care.

*Exjade* (USD 157 million) has delivered dynamic growth particularly in Europe and the Middle East since the first launch in 2006 based on its status as the first once-daily oral iron chelator for blood disorders involving chronic iron overload. Over 80 countries have approved *Exjade*, which is used to treat iron overload associated with various blood disorders. It was submitted in Japan for approval a year ahead of schedule.

*Lucentis* (USD 101 million), for the eye disease wet age-related macular degeneration (AMD), has generated rapid growth following European Union approval in January 2007. *Lucentis* is now available in 45 countries (including Switzerland, Australia and Canada) as the first and only treatment proven to maintain and improve vision in patients with wet AMD the leading cause of blindness in people over age 50. Genentech holds the US rights.

*Zelnorm/Zelmac* (USD 91 million, 66% lc), for irritable bowel syndrome and chronic constipation, has been negatively affected by the suspension of sales in the US and over 20 other countries following an FDA request in March 2007 to review cardiovascular safety data. Novartis believes *Zelnorm/Zelmac* provides important benefits for appropriate patients and will continue working with health authorities to secure access for these patients.

*Xolair* (USD 64 million), for moderate to severe allergic asthma, has grown quickly in key markets worldwide where launched, particularly France and Germany. It is now approved in 55 countries and is already available in 34 countries. In the US, Novartis co-promotes *Xolair* with Genentech and shares a portion of operating income. *Xolair* had first-half net sales of USD 231 million in the US, resulting in a contribution to Novartis of USD 79 million reported as Other Revenues.

*Prexige* (USD 52 million), an oral COX-2 inhibitor for patients with certain forms of osteoarthritic pain, gained market share where launched. EU approval was granted in November 2006, and launches are underway in Latin America, where it has performed strongly. A US regulatory decision is expected in September 2007.

*Aclasta/Reclast* was launched in April in the US after regulatory approval as the first new treatment in nearly a decade for patients with Paget's disease of the bone. *Aclasta/Reclast* is already approved in more than 50 other countries, including key European markets, for this indication. Decisions on US and European approvals are pending for the use of this medicine as a once-yearly infusion of only 15 minutes for women with postmenopausal osteoporosis.

*Exforge*, a single tablet combining the angiotensin receptor blocker valsartan (*Diovan*) and the calcium channel blocker amlodipine, was launched in the US following the earlier-than-expected final US approval in June instead of September 2007. European launches are underway in ten countries, including Germany, the UK, Greece and Switzerland following approval in January 2007, with more launches set for 2007 and 2008.

*Tekturna/Rasilez*, the first new type of high blood pressure medicine in more than a decade, has outpaced the launches of recent hypertension medicines, including Benicar<sup>®(2)</sup>, in the US following approval and launch in March. Known as *Tekturna* in the US and as *Rasilez* in other markets, key drivers have been data showing its efficacy and safety and recognition of the need for new high blood pressure medicines. *Rasilez* gained Swiss approval in June. European approval is expected during the third quarter after European regulators issued a positive opinion in June. A single-tablet combination with a diuretic was submitted for US approval during the second quarter. This medicine was developed with Speedel.

#### Research & Development update

#### Pharmaceuticals

With 138 projects in pharmaceutical development, Novartis has one of the industry's most promising pipelines. Several of the anticipated approvals are for potentially best-in-class medicines that would advance or create new treatment standards. Many compounds are progressing in late-stage trials. These include **FTY720** (multiple sclerosis), **QAB149** (respiratory diseases), **AGO178** (depression), **RAD001** (cancer), **ABF656** (hepatitis C) and **SOM 230** (Cushing's disease). Among the recent pharmaceuticals pipeline developments are:

*Tasigna* (nilotinib) is awaiting regulatory decisions in the US, Europe and Switzerland as a new targeted cancer therapy for patients with a form of the life-threatening blood cancer chronic myeloid leukemia (CML) who are resistant or intolerant to treatment with *Gleevec/Glivec* (imatinib). A submission was completed in Japan during the 2007 second quarter. Also planned for 2007 are the start of Phase III studies in newly diagnosed CML patients and patients responding sub-optimally to other therapies. A registration study is already underway in patients with gastrointestinal

stromal tumors (GIST). Both *Tasigna* and *Gleevec/Glivec* inhibit Bcr-Abl, the definitive cause of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). *Tasigna* was designed to be a more selective inhibitor of Bcr-Abl and its mutations. In the US, the FDA requested on July 16 a three-month extension in the regulatory review period.

---

(2) Benicar<sup>®</sup> is a registered trademark of Daiichi Sankyo

*Galvus* (vildagliptin), a new oral once-daily treatment for type 2 diabetes submitted for approval in the US and Europe, has been shown in new clinical data to deliver consistent and robust blood sugar reductions in patients with this progressive disease. The findings, presented at the American Diabetes Association meeting, were consistent with earlier results demonstrating the efficacy and tolerability of *Galvus* as a monotherapy and in combination with other diabetes medicines. A European Union regulatory decision is anticipated in 2007. In the US, Novartis is in discussions with the FDA on steps needed for approval after having received an approvable letter in February 2007, including a request for additional data from clinical trials.

**RAD001** (everolimus), a novel oral inhibitor of the mTOR pathway considered a key target in oncology, demonstrated its broad clinical activity in multiple tumor types in data from 17 abstracts presented at the American Society of Clinical Oncology (ASCO) meeting. Positive interim Phase II data in a proof-of-concept trial involved patients with refractory/relapsed lymphoma was presented. Registration trials are underway in chemotherapy-refractory pancreatic islet cell tumors (pICT), metastatic renal cell carcinoma and plans for expansion in 2007 include registration trials for refractory carcinoid tumors as well as first- and second-line pICT. RAD001 acts by directly inhibiting tumor cell growth and inhibiting the formation of new blood vessels (angiogenesis). First submissions could be as early as 2008.

**ACZ885**, a fully human monoclonal antibody, has entered a Phase III trial in Muckle Wells Syndrome, an inherited inflammatory disease caused by a rare genetic mutation. ACZ885 has led to immediate and long lasting clinical remission in these patients through potent and selective blockage of interleukin-1B. ACZ885 has a potentially important role in treating a range of systemic inflammatory diseases, and Phase II trials are underway in systemic juvenile arthritis and other conditions. Submissions for regulatory approval in Muckle Wells Syndrome is planned for 2009.

**NM283** (valopicitabine), in Phase IIb trials for treatment of hepatitis C, was put on clinical hold on July 13 by FDA after discussions on the overall risk/benefit profile. The affiliated company Idenix Pharmaceuticals and Novartis are evaluating options for this compound.

Novartis acquired the rights to two development compounds during the second quarter. **NIC002** (formerly CYT002-NicQb) ( NicQb ) from Cytos Biotechnology AG combines elements of medicinal and vaccine technology and has been shown in Phase II clinical trials to help smokers overcome addiction to nicotine. **ASA404** (formerly AS1404) from Antisoma plc is a small molecule vascular disrupting agent targeting solid cancer tumors and is expected to soon begin Phase III trials in patients with non-small cell lung cancer.

#### Vaccines and Diagnostics

Two important new vaccines against influenza infections received European Union approval during the 2007 second quarter: *Focetria* for use as quickly as possible after the declaration of an influenza pandemic, and *Optaflu* as the first influenza vaccine to utilize a proprietary cell culture line to generate viral antigens rather than relying on traditional chicken eggs. *Focetria* will be manufactured to contain strains declared at the

time of a pandemic by the World Health Organization (WHO). It will also include the proprietary Novartis adjuvant MF59, which could extend supplies by allowing for smaller amounts of viral antigens to be used in each dose compared to vaccines without this additive designed to increase efficacy. *Optaflu*, considered the first major innovation in influenza vaccine manufacturing in over 50 years, has been approved for use in vaccination against seasonal influenza. This cell culture technology can be used for faster and more flexible manufacturing start-up in a pandemic. It will be available in Germany and



Austria for the 2007/2008 influenza season and in other EU countries for the 2008/2009 season. Submission for US approval is planned for 2008.

**Sandoz**

European Union regulators issued a positive opinion in June supporting approval of a **biosimilar version of epoetin alfa**, as Sandoz achieved another important milestone in efforts to bring follow-on biological medicines to patients. More than 250,000 patients in Europe are treated annually with epoetin alfa, which is marketed under various brand names, and similar medicines to regulate the formation of red blood cells. The European Commission will soon decide on approval. In a precedent-setting decision in April 2006, Sandoz was the first company to obtain European Commission approval for a follow-on biologic, the human growth hormone *Omnitrope*. US approval was granted in May 2006.

## Disclaimer

This release contains certain forward-looking statements relating to the Group's business, which can be identified by the use of forward-looking terminology such as outlook, expected, will, on track, set, intends, prospects, expectations, anticipated, potential, may, plan, believes, pending, promising, pipeline, approvable, plans, could, can, or similar expressions, or by express or implied discussions regarding potential future revenues from any particular products, or potential future sales or earnings of the Novartis Group or any of its divisions; potential new products, or potential new indications for existing products, or regarding potential future revenues from any such products; or by discussions of strategy, plans, expectations or intentions. Such statements reflect the current views of management with respect to future events and are subject to certain known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any particular products will reach any particular sales levels. Neither can there be any guarantees that the Novartis Group, or any of its divisions, will achieve any particular financial results. Nor can there be any guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that they will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in the Group's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

## About Novartis

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world. For more information, please visit <http://www.novartis.com>.

## Further important dates

September 12, 2007	Novartis Brand and Business Review (East Hanover, NJ)
October 18, 2007	Nine-month and third quarter 2007 results
January 17, 2008	Full-year and fourth quarter 2007 results

## CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

## Consolidated income statements (unaudited)

## First half

	H1 2007 USD m	H1 2006 USD m	Change USD m	%
<b>Net sales from continuing operations</b>	<b>18 528</b>	<b>16 174</b>	<b>2 354</b>	<b>15</b>
Other revenues	430	253	177	70
Cost of Goods Sold	-4 985	-4 205	-780	19
<i>Of which amortization and impairments of product and patent rights and trademarks</i>	<i>-482</i>	<i>-313</i>	<i>-169</i>	<i>54</i>
<b>Gross profit</b>	<b>13 973</b>	<b>12 222</b>	<b>1 751</b>	<b>14</b>
Marketing & Sales	-5 399	-4 710	-689	15
Research & Development	-3 031	-2 377	-654	28
General & Administration	-1 000	-843	-157	19
Other Income & Expense	-111	-354	243	-69
<b>Operating income from continuing operations</b>	<b>4 432</b>	<b>3 938</b>	<b>494</b>	<b>13</b>
Income from associated companies	192	105	87	83
Financial income	177	187	-10	-5
Interest expense	-110	-133	23	-17
<b>Income before taxes from continuing operations</b>	<b>4 691</b>	<b>4 097</b>	<b>594</b>	<b>14</b>
Taxes	-656	-660	4	-1
<b>Net income from continuing operations</b>	<b>4 035</b>	<b>3 437</b>	<b>598</b>	<b>17</b>
Net income from Consumer Health discontinuing operations	152	232	-80	-34
<b>Total net income</b>	<b>4 187</b>	<b>3 669</b>	<b>518</b>	<b>14</b>
<i>Attributable to:</i>				
<i>Equity holders of Novartis AG</i>	<i>4 177</i>	<i>3 654</i>	<i>523</i>	<i>14</i>
<i>Minority interests</i>	<i>10</i>	<i>15</i>	<i>-5</i>	<i>-33</i>
<b>Average number of shares outstanding Basic (million)</b>	<b>2 342.4</b>	<b>2 342.6</b>	<b>-0.2</b>	
<b>Basic earnings per share (USD)<sup>(1)</sup></b>				
<b>Total</b>	<b>1.78</b>	<b>1.56</b>	<b>0.22</b>	<b>14</b>
<b>Continuing operations</b>	<b>1.72</b>	<b>1.46</b>	<b>0.26</b>	<b>18</b>
<b>Discontinuing operations</b>	<b>0.06</b>	<b>0.10</b>	<b>-0.04</b>	<b>-40</b>
<b>Average number of shares outstanding Diluted (million)</b>	<b>2 355.6</b>	<b>2 358.3</b>	<b>-2.7</b>	
<b>Diluted earnings per share (USD)<sup>(1)</sup></b>				
<b>Total</b>	<b>1.77</b>	<b>1.55</b>	<b>0.22</b>	<b>14</b>
<b>Continuing operations</b>	<b>1.71</b>	<b>1.45</b>	<b>0.26</b>	<b>18</b>
<b>Discontinuing operations</b>	<b>0.06</b>	<b>0.10</b>	<b>-0.04</b>	<b>-40</b>

(1) Earnings per share (EPS) is calculated on the amount of net income attributable to the equity holders of Novartis AG



## Consolidated statement of recognized income and expense (unaudited)

## First half

	H1 2007 USD m	H1 2006 USD m	Change USD m
Net income	4 187	3 669	518
Fair value adjustments on financial instruments	-16	-76	60
Actuarial gains from defined benefit plans	1 170	296	874
Additionally recognized amounts by associated companies	92	-9	101
Revaluation of initial minority interests in Chiron	55	663	-608
Translation effects	301	1 040	-739
<b>Recognized income and expense</b>	<b>5 789</b>	<b>5 583</b>	<b>206</b>

## Consolidated income statements (unaudited)

## Second quarter

	Q2 2007 USD m	Q2 2006 USD m	Change USD m	%
<b>Net sales from continuing operations</b>	<b>9 400</b>	<b>8 508</b>	<b>892</b>	<b>10</b>
Other revenues	184	163	21	13
Cost of Goods Sold	-2 497	-2 225	-272	12
<i>Of which amortization and impairments of product and patent rights and trademarks</i>	-240	-192	-48	25
<b>Gross profit</b>	<b>7 087</b>	<b>6 446</b>	<b>641</b>	<b>10</b>
Marketing & Sales	-2 812	-2 510	-302	12
Research & Development	-1 529	-1 253	-276	22
General & Administration	-517	-455	-62	14
Other Income & Expense	-132	-264	132	-50
<b>Operating income from continuing operations</b>	<b>2 097</b>	<b>1 964</b>	<b>133</b>	<b>7</b>
Income from associated companies	95	1	94	
Financial income	90	79	11	14
Interest expense	-57	-75	18	-24
<b>Income before taxes from continuing operations</b>	<b>2 225</b>	<b>1 969</b>	<b>256</b>	<b>13</b>
Taxes	-282	-317	35	-11
<b>Net income from continuing operations</b>	<b>1 943</b>	<b>1 652</b>	<b>291</b>	<b>18</b>
Net income from Consumer Health discontinuing operations	73	61	12	20
<b>Total net income</b>	<b>2 016</b>	<b>1 713</b>	<b>303</b>	<b>18</b>
<i>Attributable to:</i>				
<i>Equity holders of Novartis AG</i>	<i>2 008</i>	<i>1 707</i>	<i>301</i>	<i>18</i>
<i>Minority interests</i>	<i>8</i>	<i>6</i>	<i>2</i>	<i>33</i>
<b>Average number of shares outstanding Basic (million)</b>	<b>2 338.8</b>	<b>2 346.1</b>	<b>-7.3</b>	
<b>Basic earnings per share (USD) <sup>(1)</sup></b>				

Edgar Filing: NOVARTIS AG - Form 6-K

<b>Total</b>		<b>0.86</b>	<b>0.73</b>	<b>0.13</b>	<b>18</b>
<b>Continuing operations</b>		<b>0.83</b>	<b>0.70</b>	<b>0.13</b>	<b>19</b>
<b>Discontinuing operations</b>		<b>0.03</b>	<b>0.03</b>	<b>0</b>	
Average number of shares outstanding	Diluted (million)	2 351.6	2 361.6	-10.0	
Diluted earnings per share (USD) <sup>(1)</sup>					
Total		0.85	0.72	0.13	18
Continuing operations		0.82	0.70	0.12	17
Discontinuing operations		0.03	0.02	0.01	50

---

(1) Earnings per share (EPS) is calculated on the amount of net income attributable to the equity holders of Novartis AG

## Consolidated statement of recognized income and expense (unaudited)

## Second quarter

	Q2 2007 USD m	Q2 2006 USD m	Change USD m
Net income	2 016	1 713	303
Fair value adjustments on financial instruments	-29	-98	69
Actuarial gains from defined benefit plans	1 087	21	1 066
Additionally recognized amounts by associated companies	5	58	-53
Revaluation of initial minority interests in Chiron		663	-663
Translation effects	188	867	-679
<b>Recognized income and expense</b>	<b>3 267</b>	<b>3 224</b>	<b>43</b>

## Condensed consolidated balance sheets

## First half

	June 30, 2007 (unaudited) USD m	Dec 31, 2006 USD m	Change USD m	June 30, 2006 (unaudited) USD m
<b>Assets</b>				
<b>Non-current assets</b>				
Property, plant & equipment	11 352	10 945	407	10 077
Intangible assets	21 057	21 230	-173	21 594
Financial and other non-current assets	14 235	14 429	-194	14 463
<b>Total non-current assets</b>	<b>46 644</b>	<b>46 604</b>	<b>40</b>	<b>46 134</b>
<b>Current assets</b>				
Inventories	5 022	4 498	524	4 690
Trade accounts receivable	6 233	6 161	72	5 885
Other current assets	1 834	2 054	-220	1 910
Cash, short-term deposits and marketable securities	7 548	7 955	-407	7 310
Total current assets from continuing operations	20 637	20 668	-31	19 795
Assets related to discontinuing operations	3 340	736	2 604	
<b>Total current assets</b>	<b>23 977</b>	<b>21 404</b>	<b>2 573</b>	<b>19 795</b>
<b>Total assets</b>	<b>70 621</b>	<b>68 008</b>	<b>2 613</b>	<b>65 929</b>
<b>Equity and liabilities</b>				
<b>Total equity</b>				
	<b>43 664</b>	<b>41 294</b>	<b>2 370</b>	<b>37 164</b>
<b>Non-current liabilities</b>				
Financial debts	632	656	-24	1 617
Other non-current liabilities	8 662	9 824	-1 162	10 391
<b>Total non-current liabilities</b>	<b>9 294</b>	<b>10 480</b>	<b>-1 186</b>	<b>12 008</b>
<b>Current liabilities</b>				

Edgar Filing: NOVARTIS AG - Form 6-K

Trade accounts payable	2 509	2 487	22	2 196
Financial debts and derivatives	6 819	6 643	176	7 809
Other current liabilities	6 652	6 897	-245	6 752
Total current liabilities from continuing operations	15 980	16 027	-47	16 757
Liabilities related to discontinuing operations	1 683	207	1 476	
<b>Total current liabilities</b>	<b>17 663</b>	<b>16 234</b>	<b>1 429</b>	<b>16 757</b>
<b>Total liabilities</b>	<b>26 957</b>	<b>26 714</b>	<b>243</b>	<b>28 765</b>
<b>Total equity and liabilities</b>	<b>70 621</b>	<b>68 008</b>	<b>2 613</b>	<b>65 929</b>



## Condensed consolidated changes in equity (unaudited)

## First half

	H1 2007	H1 2006	Change
	USD m	USD m	USD m
<b>Consolidated equity at January 1</b>	<b>41 294</b>	<b>33 164</b>	<b>8 130</b>
Recognized income and expense	5 789	5 583	206
Purchase/sale of treasury shares, net	-1 095	221	-1 316
Share-based compensation	293	244	49
Dividends	-2 598	-2 049	-549
Changes in minority interests	-19	1	-20
<b>Consolidated equity at June 30</b>	<b>43 664</b>	<b>37 164</b>	<b>6 500</b>

## Second quarter

	Q2 2007	Q2 2006	Change
	USD m	USD m	USD m
<b>Consolidated equity at April 1</b>	<b>40 502</b>	<b>33 754</b>	<b>6 748</b>
Recognized income and expense	3 267	3 224	43
Purchase/sale of treasury shares, net	-248	49	-297
Share-based compensation	146	130	16
Changes in minority interests	-3	7	-10
<b>Consolidated equity at June 30</b>	<b>43 664</b>	<b>37 164</b>	<b>6 500</b>

## Condensed consolidated cash flow statements (unaudited)

## First half

	H1 2007 USD m	H1 2006 USD m	Change USD m
<b>Net income from continuing operations</b>	<b>4 035</b>	<b>3 437</b>	<b>598</b>
Reversal of non-cash items			
Taxes	656	660	-4
Depreciation, amortization and impairments	1 120	836	284
Net financial income	-67	-54	-13
Other	70	57	13
<b>Net income adjusted for non-cash items</b>	<b>5 814</b>	<b>4 936</b>	<b>878</b>
Interest and other financial receipts	300	301	-1
Interest and other financial payments	-81	-83	2
Taxes paid	-973	-1 048	75
<b>Cash flow before working capital and provision changes</b>	<b>5 060</b>	<b>4 106</b>	<b>954</b>
Restructuring payments and other cash payments out of provisions	-143	-123	-20
Change in net current assets and other operating cash flow items	-997	-387	-610
<b>Cash flow from operating activities of continuing operations</b>	<b>3 920</b>	<b>3 596</b>	<b>324</b>
Investments in property, plant & equipment	-1 145	-641	-504
Acquisitions of subsidiaries	-52	-4 290	4 238
Increase in marketable securities, intangible and financial assets	-778	-418	-360
<b>Cash flow from investing activities of continuing operations</b>	<b>-1 975</b>	<b>-5 349</b>	<b>3 374</b>
<b>Cash flow from financing activities of continuing operations</b>	<b>-3 289</b>	<b>-2 553</b>	<b>-736</b>
Cash flow from discontinuing operations	168	378	-210
Translation effect on cash and cash equivalents	24	57	-33
Change in cash and cash equivalents from discontinuing operations	-51		-51
<b>Change in cash and cash equivalents from continuing operations</b>	<b>-1 203</b>	<b>-3 871</b>	<b>2 668</b>
Cash and cash equivalents from continuing operations at January 1	3 815	6 321	-2 506
<b>Cash and cash equivalents from continuing operations at June 30</b>	<b>2 612</b>	<b>2 450</b>	<b>162</b>

## Condensed consolidated cash flow statements (unaudited)

## Second quarter

	Q2 2007 USD m	Q2 2006 USD m	Change USD m
<b>Net income from continuing operations</b>	<b>1 943</b>	<b>1 652</b>	<b>291</b>
Reversal of non-cash items			
Taxes	282	317	-35
Depreciation, amortization and impairments	580	423	157
Net financial income	-33	-4	-29
Other	21	101	-80
<b>Net income adjusted for non-cash items</b>	<b>2 793</b>	<b>2 489</b>	<b>304</b>
Interest and other financial receipts	58	81	-23
Interest and other financial payments	-44	-40	-4
Taxes paid	-690	-786	96
<b>Cash flow before working capital and provision changes</b>	<b>2 117</b>	<b>1 744</b>	<b>373</b>
Restructuring payments and other cash payments out of provisions	-64	-67	3
Change in net current assets and other operating cash flow items	-184	-93	-91
<b>Cash flow from operating activities of continuing operations</b>	<b>1 869</b>	<b>1 584</b>	<b>285</b>
Investments in property, plant & equipment	-623	-346	-277
Acquisitions of subsidiaries	-4	-4 313	4 309
Increase in marketable securities, intangible and financial assets	-181	-300	119
<b>Cash flow from investing activities of continuing operations</b>	<b>-808</b>	<b>-4 959</b>	<b>4 151</b>
<b>Cash flow from financing activities of continuing operations</b>	<b>-810</b>	<b>-798</b>	<b>-12</b>
Cash flow from discontinuing operations	79	89	-10
Translation effect on cash and cash equivalents	41	60	-19
Change in cash and cash equivalents from discontinuing operations	-49		-49
<b>Change in cash and cash equivalents from continuing operations</b>	<b>322</b>	<b>-4 024</b>	<b>4 346</b>
Cash and cash equivalents from continuing operations at April 1	2 290	6 474	-4 184
<b>Cash and cash equivalents from continuing operations at June 30</b>	<b>2 612</b>	<b>2 450</b>	<b>162</b>

## Consolidated income statements Divisional segmentation (unaudited)

## First half

	Pharmaceuticals		Vaccines and Diagnostics		Sandoz		Consumer Health continuing operations		Corporate		Total continuing operations		Consumer Health discontinuing operations		Total Group	
	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m
<b>Net sales to third parties</b>	<b>11 988</b>	<b>10 751</b>	<b>482</b>	<b>127</b>	<b>3 415</b>	<b>2 881</b>	<b>2 643</b>	<b>2 415</b>			<b>18 528</b>	<b>16 174</b>	<b>1 413</b>	<b>1 309</b>	<b>19 941</b>	<b>17 483</b>
Sales to other Divisions	86	79	6		122	75	20	23	-234	-177						
<b>Sales of Divisions</b>	<b>12 074</b>	<b>10 830</b>	<b>488</b>	<b>127</b>	<b>3 537</b>	<b>2 956</b>	<b>2 663</b>	<b>2 438</b>	<b>-234</b>	<b>-177</b>	<b>18 528</b>	<b>16 174</b>	<b>1 413</b>	<b>1 309</b>	<b>19 941</b>	<b>17 483</b>
Other revenues	189	164	213	61	11	11	17	17			430	253	6	4	436	257
Cost of Goods Sold	-2	-1			-1	-1					-4	-4			-5	-4
<i>Of which amortization and impairments of product and patent rights and trademarks</i>	-179	-91	-139	-25	-126	-157	-38	-40			-482	-313	-6	-6	-488	-319
<b>Gross profit</b>	<b>10 239</b>	<b>9 159</b>	<b>300</b>	<b>70</b>	<b>1 643</b>	<b>1 355</b>	<b>1 795</b>	<b>1 617</b>	<b>-4</b>	<b>21</b>	<b>13 973</b>	<b>12 222</b>	<b>669</b>	<b>621</b>	<b>14 642</b>	<b>12 843</b>
Marketing & Sales	-3	-3									-5	-4			-5	-5
Research & Development	-2	-1									-3	-2			-3	-2
General & Administration	430	925	-125	-37	-251	-222	-138	-115	-87	-78	031	377	-22	-19	053	396
Other Income & Expense	-368	-321	-78	-19	-164	-136	-184	-169	-206	-198	000	-843	-62	-63	062	-906
<i>Of which amortization and impairments of capitalized intangibles included in function costs</i>	-40	-15	-4		-18	-20	-3	-2	-3	-4	-68	-41	-19	-16	-87	-57
<b>Operating income</b>	<b>3 620</b>	<b>3 303</b>	<b>7</b>	<b>-38</b>	<b>561</b>	<b>445</b>	<b>483</b>	<b>446</b>	<b>-239</b>	<b>-218</b>	<b>4 432</b>	<b>3 938</b>	<b>237</b>	<b>324</b>	<b>4 669</b>	<b>4 262</b>
Income from associated companies											192	105		192	105	
Financial income											177	187		177	187	
Interest expense											-110	-133		-110	-133	
<b>Income before taxes</b>											<b>4 691</b>	<b>4 097</b>	<b>237</b>	<b>324</b>	<b>4 928</b>	<b>4 421</b>
Taxes											-656	-660	-85	-92	-741	-752
<b>Net income</b>											<b>4 035</b>	<b>3 437</b>	<b>152</b>	<b>232</b>	<b>4 187</b>	<b>3 669</b>

Edgar Filing: NOVARTIS AG - Form 6-K

*Additions to:*

*- Property, plant  
and*

*equipment(1)*      690      399      92      27      251      113      90      69      32      39      1 155      647      23      16      1 178      663

*- Goodwill and  
other*

*intangibles(1)*      221      271                15      11      2      103      4           242      385      71      33      313      418

---

(1) Excluding impact of business acquisitions

## Consolidated income statements Divisional segmentation (unaudited)

## Second quarter

	Pharmaceuticals		Vaccines and Diagnostics		Sandoz		Consumer Health continuing operations		Corporate		Total continuing operations		Consumer Health discontinuing operations		Total Group	
	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m
<b>Net sales to third parties</b>	<b>6 065</b>	<b>5 699</b>	<b>251</b>	<b>127</b>	<b>1 719</b>	<b>1 450</b>	<b>1 365</b>	<b>1 232</b>			<b>9 400</b>	<b>8 508</b>	<b>722</b>	<b>674</b>	<b>10 122</b>	<b>9 182</b>
Sales to other Divisions	43	41	2		56	37	10	18	-111	-96						
<b>Sales of Divisions</b>	<b>6 108</b>	<b>5 740</b>	<b>253</b>	<b>127</b>	<b>1 775</b>	<b>1 487</b>	<b>1 375</b>	<b>1 250</b>	<b>-111</b>	<b>-96</b>	<b>9 400</b>	<b>8 508</b>	<b>722</b>	<b>674</b>	<b>10 122</b>	<b>9 182</b>
Other revenues	89	87	78	61	9	7	8	8			184	163	4	1	188	164
Cost of Goods Sold	-1										-2	-2			-2	-2
<i>Of which amortization and impairments of product and patent rights and trademarks</i>	-90	-51	-68	-25	-62	-97	-20	-19			-240	-192	-3	-3	-243	-195
<b>Gross profit</b>	<b>5 184</b>	<b>4 888</b>	<b>142</b>	<b>70</b>	<b>830</b>	<b>664</b>	<b>926</b>	<b>821</b>	<b>5</b>	<b>3</b>	<b>7 087</b>	<b>6 446</b>	<b>340</b>	<b>315</b>	<b>7 427</b>	<b>6 761</b>
Marketing & Sales	-1	-1									-2	-2			-2	-2
Research & Development	959	764	-49	-27	-298	-256	-506	-463			812	510	-177	-172	989	682
General & Administration	-1										-1	-1			-1	-1
Other Income & Expense	215	-999	-71	-37	-127	-117	-72	-59	-44	-41	529	253	-12	-9	541	262
<i>Of which amortization and impairments of capitalized intangibles included in function costs</i>	-196	-176	-37	-19	-87	-68	-93	-88	-104	-104	-517	-455	-31	-32	-548	-487
<b>Operating income</b>	<b>-47</b>	<b>-272</b>	<b>-5</b>	<b>-25</b>	<b>-75</b>	<b>-16</b>	<b>-12</b>	<b>5</b>	<b>7</b>	<b>44</b>	<b>-132</b>	<b>-264</b>	<b>-1</b>	<b>-6</b>	<b>-133</b>	<b>-270</b>
Income from associated companies																
Financial income											95	1			95	1
Interest expense											90	79			90	79
<b>Income before taxes</b>											<b>2 225</b>	<b>1 969</b>	<b>119</b>	<b>96</b>	<b>2 344</b>	<b>2 065</b>
Taxes											-282	-317	-46	-35	-328	-352
<b>Net income</b>											<b>1 943</b>	<b>1 652</b>	<b>73</b>	<b>61</b>	<b>2 016</b>	<b>1 713</b>

Edgar Filing: NOVARTIS AG - Form 6-K

Additions to:

- Property, plant  
and  
equipment(1)

361 251 48 27 161 26 43 32 8 11 621 347 17 7 638 354

- Goodwill and  
other  
intangibles(1)

145 197 4 8 1 103 4 154 308 48 14 202 322

---

(1) Excluding impact of business acquisitions

**Notes to the Condensed Interim Consolidated Financial Statements for the six months ended June 30, 2007 (unaudited)**

**1. Basis of preparation**

The condensed consolidated financial statements for the six-month period ended June 30, 2007, have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and with accounting policies set out in the 2006 Annual Report, which was published on January 18, 2007.

**2. Business combinations and other significant transactions**

The following significant transactions occurred during 2007 and 2006:

**2007**

**Consumer Health Gerber business unit divestment**

On April 12, Novartis announced an agreement to divest the Gerber business unit for approximately USD 5.5 billion to Nestlé S.A. This transaction, which is subject to customary regulatory approvals, is expected to be completed in the second half of 2007. Gerber had 2006 net sales of USD 1.6 billion and operating income of USD 307 million.

**Consumer Health Medical Nutrition business unit divestment (Q3 2007 event)**

On July 1, Novartis completed the divestment of the remainder of the Medical Nutrition Business Unit for USD 2.5 billion to Nestlé S.A. An after-tax divestment gain of approximately USD 1.5 billion will be recorded in the third quarter.

The Gerber and Medical Nutrition business units (which included the Nutrition & Santé business divested in February 2006) are disclosed as discontinuing operations in all periods in the Group's consolidated financial statements

**2006**

**Corporate Chiron acquisition**



## Edgar Filing: NOVARTIS AG - Form 6-K

On April 19, Chiron shareholders approved the acquisition of the remaining 56% of the shares of Chiron Corporation that Novartis did not already own for USD 48.00 per share. The amount paid for the shares, related options of associates and transaction costs totaled approximately USD 5.7 billion. The transaction was completed on April 20. Novartis has created a new division called Vaccines and Diagnostics with two activities: human vaccines named Novartis Vaccines and a diagnostics activity that retained Chiron as its name. Chiron's biopharmaceuticals activities were integrated into the Pharmaceuticals Division.

For the period from January 1 to the date of acquisition, the prior 44% interest in Chiron has been accounted for using the equity method. From its date of acquisition Chiron has been fully consolidated with its identifiable assets and liabilities being revalued to their fair value at the date of acquisition. The Group's initial 44% interest in Chiron also was revalued directly into equity by USD 0.6 billion.

## Pharmaceuticals

As part of the Chiron transaction, Chiron's pharmaceuticals activities have been integrated into the Pharmaceuticals Division. Included in this portfolio are products for the treatment of cystic fibrosis, renal/skin cancer and skin infections. Chiron's early-stage research has been incorporated into the Pharmaceuticals Division research unit, the Novartis Institutes for BioMedical Research (NIBR). Since the acquisition, the income statement and cash flows from Chiron's pharmaceuticals activities have been consolidated into the Division's results.

On March 26, 2007, an agreement was reached with Bayer-Schering AG on the rights of each party in connection with the regulatory, development, manufacturing and supply agreements for the multiple sclerosis medicine Betaseron®. Due to this agreement, a reassessment has been made as of April 20, 2006, for the values for the related assets. This resulted in an increase of USD 235 million in identified net assets. Goodwill and the revaluation of the initial 44% interest in Chiron were adjusted accordingly and recorded in the 2007 first quarter. Final goodwill on this transaction at June 30, 2007, amounted to USD 1.9 billion.

On July 14, 2006, Novartis announced that its offer for the UK biopharmaceutical company NeuTec Pharma plc, which is specialized in hospital anti-infectives, became unconditional and the company has been consolidated from this date. Novartis paid a total consideration of USD 606 million (GBP 328 million) to fully acquire the company. NeuTec Pharma plc has had no post-acquisition sales, although expenses and cash flows were consolidated from the acquisition date. Goodwill at June 30, 2007, amounted to USD 137 million.

## Vaccines and Diagnostics

Since the Chiron acquisition, the income statement and cash flows from the vaccines and diagnostics activities comprise the Division's results. Goodwill on this transaction at June 30, 2007, amounted to USD 1.1 billion.

### 3. Principal currency translation rates

#### First half

	Average rates H1 2007	Average rates H1 2006	Period-end rates June 30, 2007	Period-end rates June 30, 2006
	USD	USD	USD	USD
1 CHF	<b>0.815</b>	0.787	<b>0.813</b>	0.811
1 EUR	<b>1.329</b>	1.229	<b>1.346</b>	1.270
1 GBP	<b>1.971</b>	1.789	<b>2.005</b>	1.833
100 JPY	<b>0.833</b>	0.865	<b>0.811</b>	0.872

#### Second quarter

	Average rates Q2 2007	Average rates Q2 2006	Period-end rates June 30, 2007	Period-end rates June 30, 2006
	USD	USD	USD	USD
1 CHF	<b>0.818</b>	0.803	<b>0.813</b>	0.811
1 EUR	<b>1.348</b>	1.256	<b>1.346</b>	1.270
1 GBP	<b>1.987</b>	1.825	<b>2.005</b>	1.833
100 JPY	<b>0.828</b>	0.874	<b>0.811</b>	0.872

#### 4. Legal proceedings update

A number of our affiliates are the subject of various legal proceedings that arise from time to time in the ordinary course of business. While we do not believe that any of them will have a material adverse effect on our financial position, litigation is inherently unpredictable and excessive verdicts do occur. As a consequence, we may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period. Please consult the 2006 Annual Report (note 19 to the Group's consolidated financial statements) for a summary of major legal proceedings. The following non-exhaustive list reflects recent developments in legal proceedings:

##### Product liability litigation

###### *Zometa/Aredia*

A Novartis affiliate is a defendant in now approximately 297 cases, brought in US courts by approximately 333 plaintiffs who claim to have experienced osteonecrosis of the jaw after having been treated with *Zometa/Aredia*. Three of these cases purport to be class actions. Discovery is continuing in these cases.

###### *Zelnorm/Zelmac*

Novartis affiliates are defendants in three lawsuits filed in US state courts. Plaintiffs claim to have experienced permanent injuries, including severe chest pain, angina and heart attack. These cases are at an early stage.

##### Patent litigation

###### *Lotrel*

Novartis is involved in US patent litigation involving *Lotrel*, a single-capsule combination of the high blood pressure medicines benazepril hydrochloride and amlodipine besylate sold only in the United States. Patent protection for both of these active ingredients has ended in the US, most recently for amlodipine besylate in March 2007. However, *Lotrel* is still protected by a combination patent in the US valid until 2017, and Novartis filed infringement lawsuits against generic manufacturers that challenged this patent. In March 2007, Novartis filed a motion for preliminary injunction to stop an at-risk launch by Teva Pharmaceuticals, which was denied. Teva then elected in May 2007 to launch its generic version in the US. A trial date has not been set for the ongoing patent infringement lawsuit. Novartis will continue to pursue its claims against Teva for damages and injunctive relief.

###### *Famvir*

*Famvir*, a therapy for viral infections, is the subject of patent litigation in the US. The active ingredient is covered by a compound patent that expires in 2010 in the US and in 2008 in Europe, but expired in Canada in 2006. Various method-of-use patents expire in 2014 and 2015. Novartis initiated litigation against Teva for infringement of the compound patent. In June 2007, Teva received tentative FDA approval for its generic version, but this does not impact on the validity of these patents. Novartis will continue to vigorously defend its intellectual property rights.

*Contact lenses*

Rembrandt Vision Technologies filed a patent infringement suit against CIBA Vision in October 2005. The asserted patent relates to the surface treatment of lenses and involves CIBA Vision's O2OPTIX and NIGHT & DAY products. A so-called Markman order was issued by a Texas federal court.

**5. Significant differences between IFRS and US Generally Accepted Accounting Principles (US GAAP)**

The Group's consolidated financial statements have been prepared in accordance with IFRS, which, as applied by the Group, differ in certain significant respects from US GAAP. The effects of the application of US GAAP to net income and equity are set out in the tables below.

For further comments regarding the nature of these adjustments, please consult note 33 in the Novartis 2006 Annual Report.

	H1 2007 USD m	H1 2006 USD m
<b>Net income from continuing operations under IFRS</b>	<b>4 035</b>	<b>3 437</b>
US GAAP adjustments:		
Available-for-sale securities	-15	-88
Inventory impairment reversal	-76	46
Intangible assets	-328	-369
Property, plant and equipment	3	30
Pensions and other post-employment benefits	-88	-85
Deferred taxes	99	-201
Share-based compensation	-1	-2
Currency translation		-3
Minority interests	-10	-15
Other	-58	-11
<b>Net income from continuing operations under US GAAP</b>	<b>3 561</b>	<b>2 739</b>
Net income from discontinuing operations under US GAAP	152	163
<b>Net income under US GAAP</b>	<b>3 713</b>	<b>2 902</b>
<b>Basic earnings per share under US GAAP (USD)</b>		
Total	1.59	1.24
Continuing operations	1.52	1.17
Discontinuing operations	0.07	0.07
<b>Diluted earnings per share under US GAAP (USD)</b>		
Total	1.58	1.23
Continuing operations	1.51	1.16
Discontinuing operations	0.07	0.07

	June 30, 2007 USD m	June 30, 2006 USD m
<b>Equity under IFRS</b>	<b>43 664</b>	<b>37 164</b>
US GAAP adjustments:		
Available-for-sale securities	-35	-23
Inventory impairment reversal	-87	-78
Associated companies	-304	-303
Intangible assets	-2 132	2 681
Property, plant and equipment	-427	-398
Pensions and other post-employment benefits	13	2 606
Deferred taxes	313	-965
Share-based compensation	-98	-94
Minority interests	-179	-189
Net assets from discontinuing operations	2 851	-19

Other	51	22
<b>Total US GAAP adjustments</b>	<b>-34</b>	<b>3 240</b>
<b>Equity under US GAAP</b>	<b>43 630</b>	<b>40 404</b>

## Supplementary information (unaudited)

## Condensed consolidated change in liquidity

## First half

	H1 2007 USD m	H1 2006 USD m	Change USD m
<b>Change in cash and cash equivalents</b>	<b>-1 203</b>	<b>-3 871</b>	<b>2 668</b>
Change in marketable securities, financial debt and financial derivatives	644	-724	1 368
<b>Change in net liquidity</b>	<b>-559</b>	<b>-4 595</b>	<b>4 036</b>
Net liquidity at January 1	656	2 479	-1 823
<b>Net liquidity/debt from continuing operations at June 30</b>	<b>97</b>	<b>-2 116</b>	<b>2 213</b>
Net liquidity from discontinuing operations at June 30	-8		-8
<b>Net liquidity/debt at June 30</b>	<b>89</b>	<b>-2 116</b>	<b>2 205</b>

## Second quarter

	Q2 2007 USD m	Q2 2006 USD m	Change USD m
<b>Change in cash and cash equivalents</b>	<b>322</b>	<b>-4 024</b>	<b>4 346</b>
Change in marketable securities, financial debt and financial derivatives	168	-1 115	1 283
<b>Change in net liquidity</b>	<b>490</b>	<b>-5 139</b>	<b>5 629</b>
Net liquidity at April 1	-393	3 023	-3 416
<b>Net liquidity/debt from continuing operations at June 30</b>	<b>97</b>	<b>-2 116</b>	<b>2 213</b>
Net liquidity from discontinuing operations at June 30	-8		-8
<b>Net liquidity/debt at June 30</b>	<b>89</b>	<b>-2 116</b>	<b>2 205</b>



**Free cash flow****First half**

	H1 2007 USD m	H1 2006 USD m	Change USD m
<b>Cash flow from continuing operating activities</b>	<b>3 920</b>	<b>3 596</b>	<b>324</b>
Purchase of property, plant & equipment	-1 145	-641	-504
Purchase of intangible and financial assets	-322	-473	151
Sale of property, plant & equipment, intangible and financial assets	256	171	85
Dividends	-2 598	-2 049	-549
<b>Free cash flow from continuing operations</b>	<b>111</b>	<b>604</b>	<b>-493</b>
Free cash flow from discontinuing operations	111	192	-81
<b>Total free cash flow</b>	<b>222</b>	<b>796</b>	<b>-574</b>

**Second quarter**

	Q2 2007 USD m	Q2 2006 USD m	Change USD m
<b>Cash flow from continuing operating activities</b>	<b>1 869</b>	<b>1 584</b>	<b>285</b>
Purchase of property, plant & equipment	-623	-346	-277
Purchase of intangible and financial assets	-210	-348	138
Sale of property, plant & equipment, intangible and financial assets	233	57	176
Dividends	-806	-644	-162
<b>Free cash flow from continuing operations</b>	<b>463</b>	<b>303</b>	<b>160</b>
Free cash flow from discontinuing operations	15	120	-105
<b>Total free cash flow</b>	<b>478</b>	<b>423</b>	<b>55</b>

**Share information**

	June 30, 2007	June 30, 2006
Number of shares outstanding (million)	2 334.9	2 346.9
Registered share price (CHF)	69.0	66.20
ADS price (USD)	56.07	53.92
Market capitalization (USD billion)	131.0	125.9
Market capitalization (CHF billion)	161.1	155.4

## Impact of intangible asset charges and significant exceptional items First half

	Pharmaceuticals		Vaccines and Diagnostics		Sandoz		Consumer Health continuing operations		Corporate		Total continuing operations		Consumer Health discontinuing operations		Total Group	
	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m	H1 2007 USD m	H1 2006 USD m
<b>Reported operating income</b>	<b>3 620</b>	<b>3 303</b>	<b>7</b>	<b>-38</b>	<b>561</b>	<b>445</b>	<b>483</b>	<b>446</b>	<b>-239</b>	<b>-218</b>	<b>4 432</b>	<b>3 938</b>	<b>237</b>	<b>324</b>	<b>4 669</b>	<b>4 262</b>
Recurring amortization	205	99	143	25	144	138	41	41	3	4	536	307	25	22	561	329
Impairments	14	7				39		1			14	47			14	47
<b>Intangible asset charges</b>	<b>219</b>	<b>106</b>	<b>143</b>	<b>25</b>	<b>144</b>	<b>177</b>	<b>41</b>	<b>42</b>	<b>3</b>	<b>4</b>	<b>550</b>	<b>354</b>	<b>25</b>	<b>22</b>	<b>575</b>	<b>376</b>
Impairment charges on property, plant & equipment		-2			18	7					18	5			18	5
Impact of increasing acquisition related inventory to selling price less distribution margin		44		23			3				3	67		3	3	70
Restructuring and acquisition related integration expenses, net		89	10	19	7	17	3				20	125			20	125
<b>Exceptional restructuring and acquisition-related integration expenses, net</b>		<b>131</b>	<b>10</b>	<b>42</b>	<b>25</b>	<b>24</b>	<b>6</b>				<b>41</b>	<b>197</b>		<b>3</b>	<b>41</b>	<b>200</b>
<b>Exceptional gains from divesting subsidiaries and major products</b>		<b>-87</b>										<b>-87</b>		<b>-129</b>		<b>-216</b>
Impairment of financial assets	3	19			10				4	2	17	21			17	21
Litigation and other settlements			-83								-83				-83	
Suspension of <i>Zelnorm</i>	71										71				71	
<i>Tekturma</i> inventory provision	-107										-107				-107	
<b>Other exceptional items</b>	<b>-33</b>	<b>19</b>	<b>-83</b>		<b>10</b>				<b>4</b>	<b>2</b>	<b>-102</b>	<b>21</b>			<b>-102</b>	<b>21</b>
<b>Operating income excluding the above items</b>	<b>3 806</b>	<b>3 472</b>	<b>77</b>	<b>29</b>	<b>740</b>	<b>646</b>	<b>530</b>	<b>488</b>	<b>-232</b>	<b>-212</b>	<b>4 921</b>	<b>4 423</b>	<b>262</b>	<b>220</b>	<b>5 183</b>	<b>4 643</b>
Income from associated companies											192	105			192	105
Exceptional associated companies/ Chiron-related acquisition charges												53				53
Net financial income											67	54			67	54
Taxes (adjusted for above items)											-834	-839	-93	-82	-927	-921
<b>Adjusted net income</b>											<b>4 346</b>	<b>3 796</b>	<b>169</b>	<b>138</b>	<b>4 515</b>	<b>3 934</b>
<b>Adjusted net income attributable to shareholders</b>											<b>4 336</b>	<b>3 781</b>	<b>169</b>	<b>138</b>	<b>4 505</b>	<b>3 919</b>
<b>Adjusted basic earnings per share</b>											<b>1.85</b>	<b>1.61</b>	<b>0.07</b>	<b>0.06</b>	<b>1.92</b>	<b>1.67</b>



## Impact of intangible asset charges and significant exceptional items Second quarter

	Pharmaceuticals		Vaccines and Diagnostics		Sandoz		Consumer Health continuing operations		Corporate		Total continuing operations		Consumer Health discontinuing operations		Total Group	
	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m	Q2 2007 USD m	Q2 2006 USD m
<b>Reported operating income</b>	<b>1 767</b>	<b>1 677</b>	<b>-20</b>	<b>-38</b>	<b>243</b>	<b>207</b>	<b>243</b>	<b>216</b>	<b>-136</b>	<b>-98</b>	<b>2 097</b>	<b>1 964</b>	<b>119</b>	<b>96</b>	<b>2 216</b>	<b>2 060</b>
Recurring amortization	103	56	72	25	73	70	21	21	2	2	271	174	13	11	284	185
Impairments	6	3				39					6	42			6	42
<b>Intangible asset charges</b>	<b>109</b>	<b>59</b>	<b>72</b>	<b>25</b>	<b>73</b>	<b>109</b>	<b>21</b>	<b>21</b>	<b>2</b>	<b>2</b>	<b>277</b>	<b>216</b>	<b>13</b>	<b>11</b>	<b>290</b>	<b>227</b>
Impairment charges on property, plant & equipment		-1			18						18	-1			18	-1
Impact of increasing acquisition related inventory to selling price less distribution margin		44		23			3				3	67		3	3	70
Restructuring and acquisition related integration expenses, net		89	3	19		1	3				6	109			6	109
<b>Exceptional restructuring and acquisition-related integration expenses, net</b>		<b>132</b>	<b>3</b>	<b>42</b>	<b>18</b>	<b>1</b>	<b>6</b>				<b>27</b>	<b>175</b>		<b>3</b>	<b>27</b>	<b>178</b>
Impairment of financial assets	2	5			10						12	5			12	5
Litigation and other settlements			-16								-16				-16	
Suspension of <i>Zelnorm</i> <i>Tekturna</i> inventory provision	19										19				19	
<b>Other exceptional items</b>	<b>21</b>	<b>5</b>	<b>-16</b>		<b>10</b>						<b>15</b>	<b>5</b>			<b>15</b>	<b>5</b>
<b>Operating income excluding the above items</b>	<b>1 897</b>	<b>1 873</b>	<b>39</b>	<b>29</b>	<b>344</b>	<b>317</b>	<b>270</b>	<b>237</b>	<b>-134</b>	<b>-96</b>	<b>2 416</b>	<b>2 360</b>	<b>132</b>	<b>110</b>	<b>2 548</b>	<b>2 470</b>
Income from associated companies											95	1			95	1
Exceptional associated companies/ Chiron-related acquisition charges												53				53
Net financial income											33	4			33	4
Taxes (adjusted for above items)											-394	-466	-50	-41	-444	-507
<b>Adjusted net income</b>											<b>2 150</b>	<b>1 952</b>	<b>82</b>	<b>69</b>	<b>2 232</b>	<b>2 021</b>
<b>Net income attributable to shareholders</b>											<b>2 142</b>	<b>1 946</b>	<b>82</b>	<b>69</b>	<b>2 224</b>	<b>2 015</b>
<b>Adjusted basic earnings per share</b>											<b>0.92</b>	<b>0.83</b>	<b>0.03</b>	<b>0.03</b>	<b>0.95</b>	<b>0.86</b>



## Supplementary tables: First half 2007 net sales of top 20 pharmaceutical products (unaudited)

Brands	Therapeutic area	US		Rest of world		Total		
		USD m	% change in local currencies	USD m	% change in local currencies	in USD	% change in local currencies	
<i>Diovan/Co Diovan</i>	Hypertension	1 069	24	1 321	14	2 390	21	19
<i>Gleevec/Glivec</i>	Chronic myeloid leukemia	333	15	1 088	14	1 421	19	14
<i>Zometa</i>	Cancer complications	319	-9	317	9	636	1	-1
<i>Lotrel</i>	Hypertension	594	-8			594	-8	-8
<i>Sandostatin (group)</i>	Acromegaly	198	14	293	4	491	12	8
<i>Neoral/Sandimmun</i>	Transplantation	56	-11	401	-1	457	2	-2
<i>Femara</i>	Breast cancer	199	28	240	32	439	35	30
<i>Lamisil (group)</i>	Fungal infections	262	-10	170	-13	432	-11	-11
<i>Trileptal</i>	Epilepsy	300	12	96	8	396	13	11
<i>Voltaren (group)</i>	Inflammation/pain	2	-67	354	4	356	6	3
<b>Top ten products total</b>		<b>3 332</b>	<b>7</b>	<b>4 280</b>	<b>10</b>	<b>7 612</b>	<b>11</b>	<b>9</b>
<i>Lescol</i>	Cholesterol reduction	107	-11	232	-7	339	-5	-8
<i>Exelon</i>	Alzheimer s disease	98	17	199	17	297	22	17
<i>Tegretol (incl. CR/XR)</i>	Epilepsy	63	7	141	1	204	6	3
<i>Comtan/Stalevo (group)</i>	Parkinson s disease	87	19	113	26	200	27	23
<i>Ritalin (group)</i>	Attention deficit/Hyperactive disorder	157	29	36	5	193	25	24
<i>Foradil</i>	Asthma	10	43	170	2	180	10	4
<i>Exjade (group)</i>	Iron chelator	85	85	72		157	214	205
<i>Miacalcic</i>	Osteoporosis	78	-26	65	-15	143	-20	-22
<i>Famvir</i>	Viral infections	95	25	47	-15	142	11	9
<i>TOBI<sup>(1)</sup></i>	Cystic fibrosis	85	193	49	228	134	205	202
<b>Top 20 products total</b>		<b>4 197</b>	<b>10</b>	<b>5 404</b>	<b>10</b>	<b>9 601</b>	<b>13</b>	<b>10</b>
Rest of portfolio		547	-20	1 840	13	2 387	6	3
<b>Total Division sales</b>		<b>4 744</b>	<b>5</b>	<b>7 244</b>	<b>11</b>	<b>11 988</b>	<b>12</b>	<b>9</b>

(1) Acquired on April 20, 2006, through the purchase of Chiron

## Supplementary tables: Second quarter 2007 net sales of top 20 pharmaceutical products (unaudited)

Brands	Therapeutic area	US		Rest of world			Total	
		USD m	% change in local currencies	USD m	% change in local currencies	USD m	in USD	% change in local currencies
<i>Diovan/Co Diovan</i>	Hypertension	546	22	693	13	1 239	19	17
<i>Gleevec/Glivec</i>	Chronic myeloid leukemia	177	13	570	12	747	17	12
<i>Zometa</i>	Cancer complications	160	-4	162	9	322	5	2
<i>Lotrel</i>	Hypertension	241	-31			241	-31	-31
<i>Sandostatin (group)</i>	Acromegaly	103	21	150	3	253	13	0
<i>Neoral/Sandimmun</i>	Transplantation	26	-13	207	-3	233	-1	-4
<i>Femara</i>	Breast cancer	103	23	128	33	231	33	28
<i>Lamisil (group)</i>	Fungal infections	130	-24	95	-16	225	-20	-21
<i>Trileptal</i>	Epilepsy	150	6	49	4	199	7	5
<i>Voltaren (group)</i>	Inflammation/pain	0	-100	185	3	185	5	2
<b>Top ten products total</b>		<b>1 636</b>	<b>0</b>	<b>2 239</b>	<b>9</b>	<b>3 875</b>	<b>7</b>	<b>5</b>
<i>Lescol</i>	Cholesterol reduction	51	-12	117	-6	168	-6	-8
<i>Exelon</i>	Alzheimer s disease	48	14	103	13	151	18	13
<i>Tegretol (incl. CR/XR)</i>	Epilepsy	31	0	74	4	105	7	3
<i>Comtan/Stalevo (group)</i>	Parkinson s disease	45	22	61	29	106	31	26
<i>Ritalin (group)</i>	Attention deficit/Hyperactive disorder	72	20	20	6	92	19	17
<i>Foradil</i>	Asthma	4	33	88	10	92	19	12
<i>Exjade (group)</i>	Iron chelator	46	64	46	92	197	185	
<i>Miacalcic</i>	Osteoporosis	37	-30	32	-19	69	-24	-26
<i>Famvir</i>	Viral infections	48	20	24	-17	72	7	4
<i>TOBI<sup>(1)</sup></i>	Cystic fibrosis	41	41	24	61	65	48	48
<b>Top 20 products total</b>		<b>2 059</b>	<b>2</b>	<b>2 828</b>	<b>9</b>	<b>4 887</b>	<b>9</b>	<b>6</b>
Rest of portfolio		222	-44	956	14	1 178	-3	-6
<b>Total Division sales</b>		<b>2 281</b>	<b>-6</b>	<b>3 784</b>	<b>10</b>	<b>6 065</b>	<b>6</b>	<b>4</b>

(1) Acquired on April 20, 2006, through the purchase of Chiron

**Pharmaceutical division: First half net sales by therapeutic area**  
(unaudited)

	H1 2007 USD m	H1 2006 USD m	% change USD
<b>Cardiovascular</b>			
<i>Diovan</i>	2 390	1 983	21
<i>Lotrel</i>	594	643	-8
Other	40	4	900
<b>Total strategic franchise products</b>	<b>3 024</b>	<b>2 630</b>	<b>15</b>
<b>Mature products</b>	<b>749</b>	<b>755</b>	<b>-1</b>
<b>Total Cardiovascular products</b>	<b>3 773</b>	<b>3 385</b>	<b>11</b>
<b>Oncology</b>			
<i>Gleevec/Glivec</i>	1 421	1 199	19
<i>Zometa</i>	636	627	1
<i>Sandostatin (group)</i>	491	439	12
<i>Femara</i>	439	326	35
<i>Exjade</i>	157	50	214
Other	138	147	-6
<b>Total Oncology products</b>	<b>3 282</b>	<b>2 788</b>	<b>18</b>
<b>Neuroscience</b>			
<i>Trileptal</i>	396	352	13
<i>Exelon</i>	297	244	22
<i>Tegretol</i>	204	192	6
<i>Comtan (group)</i>	200	158	27
<i>Ritalin (group)</i>	193	155	25
Other	215	139	55
<b>Total strategic franchise products</b>	<b>1 505</b>	<b>1 240</b>	<b>21</b>
<b>Mature products</b>	<b>210</b>	<b>222</b>	<b>-5</b>
<b>Total Neuroscience products</b>	<b>1 715</b>	<b>1 462</b>	<b>17</b>
<b>Respiratory</b>			
<i>Foradil</i>	180	164	10
<i>TOBI<sup>(1)</sup></i>	134	44	205
<i>Xolair</i>	64	41	56
Other	40	34	18
<b>Total strategic franchise products</b>	<b>418</b>	<b>283</b>	<b>48</b>
<b>Mature products</b>	<b>52</b>	<b>56</b>	<b>-7</b>
<b>Total Respiratory products</b>	<b>470</b>	<b>339</b>	<b>39</b>
<b>Ophthalmics/Dermatology/Gastrointestinal/Urinary (ODGU)</b>			
<i>Lucentis</i>	101	3	
<i>Elidel</i>	94	91	3
<i>Zelnorm/Zelmac</i>	91	263	-65
<i>Enablex/Emselex</i>	81	47	72
Other	318	387	-18
<b>Total strategic franchise products</b>	<b>685</b>	<b>791</b>	<b>-13</b>
<b>Mature products</b>	<b>488</b>	<b>540</b>	<b>-10</b>
<b>Total ODGU products</b>	<b>1 173</b>	<b>1 331</b>	<b>-12</b>
<b>Arthritis/Bone/Pain</b>			
<i>Prexige</i>	52	14	271



Other	5	1	400
<b>Total strategic franchise products</b>	<b>57</b>	<b>15</b>	<b>280</b>
Mature products (including <i>Voltaren</i> )	702	711	-1
<b>Total Arthritis/Bone/Pain products</b>	<b>759</b>	<b>726</b>	<b>5</b>
<b>Infectious Diseases, Transplantation &amp; Immunology (IDTI)</b>			
<i>Neoral/Sandimmun</i>	457	449	2
Other	202	148	36
<b>Total strategic franchise products</b>	<b>659</b>	<b>597</b>	<b>10</b>
<b>Mature products</b>	<b>157</b>	<b>123</b>	<b>28</b>
<b>Total IDTI products</b>	<b>816</b>	<b>720</b>	<b>13</b>
<b>Total strategic franchise products</b>	<b>9 630</b>	<b>8 344</b>	<b>15</b>
<b>Total mature products</b>	<b>2 358</b>	<b>2 407</b>	<b>-2</b>
<b>Total division net sales</b>	<b>11 988</b>	<b>10 751</b>	<b>12</b>

---

(1) Acquired on April 20, 2006, through the purchase of Chiron

**Pharmaceutical division: Second quarter net sales by therapeutic area**  
(unaudited)

	Q2 2007 USD m	Q2 2006 USD m	% change USD
<b>Cardiovascular</b>			
<i>Diovan</i>	1 239	1 044	19
<i>Lotrel</i>	241	348	-31
Other	24	2	
<b>Total strategic franchise products</b>	<b>1 504</b>	<b>1 394</b>	<b>8</b>
<b>Mature products</b>	<b>372</b>	<b>377</b>	<b>-1</b>
<b>Total Cardiovascular products</b>	<b>1 876</b>	<b>1 771</b>	<b>6</b>
<b>Oncology</b>			
<i>Gleevec/Glivec</i>	747	640	17
<i>Zometa</i>	322	308	5
<i>Sandostatin (group)</i>	253	223	13
<i>Femara</i>	231	174	33
<i>Exjade</i>	92	31	197
Other	69	84	-18
<b>Total Oncology products</b>	<b>1 714</b>	<b>1 460</b>	<b>17</b>
<b>Neuroscience</b>			
<i>Trileptal</i>	199	186	7
<i>Exelon</i>	151	128	18
<i>Tegretol</i>	105	98	7
<i>Comtan (group)</i>	106	81	31
<i>Ritalin (group)</i>	92	77	19
Other	106	85	25
<b>Total strategic franchise products</b>	<b>759</b>	<b>655</b>	<b>16</b>
<b>Mature products</b>	<b>107</b>	<b>114</b>	<b>-6</b>
<b>Total Neuroscience products</b>	<b>866</b>	<b>769</b>	<b>13</b>
<b>Respiratory</b>			
<i>Foradil</i>	92	77	19
<i>TOBI<sup>(1)</sup></i>	65	44	48
<i>Xolair</i>	30	37	-19
Other	20	17	18
<b>Total strategic franchise products</b>	<b>207</b>	<b>175</b>	<b>18</b>
<b>Mature products</b>	<b>23</b>	<b>27</b>	<b>-15</b>
<b>Total Respiratory products</b>	<b>230</b>	<b>202</b>	<b>14</b>
<b>Ophthalmics/Dermatology/Gastrointestinal/Urinary (ODGU)</b>			
<i>Lucentis</i>	72	2	
<i>Elidel</i>	47	43	9
<i>Zelnorm/Zelmac</i>	-14	154	
<i>Enablex/Emselex</i>	43	26	65
Other	161	199	-19
<b>Total strategic franchise products</b>	<b>309</b>	<b>424</b>	<b>-27</b>
<b>Mature products</b>	<b>253</b>	<b>314</b>	<b>-19</b>
<b>Total ODGU products</b>	<b>562</b>	<b>738</b>	<b>-24</b>
<b>Arthritis/Bone/Pain</b>			
<i>Prexige</i>	31	9	244

Other	3	1	200
<b>Total strategic franchise products</b>	<b>34</b>	<b>10</b>	<b>240</b>
Mature products (including <i>Voltaren</i> )	358	366	-2
<b>Total Arthritis/Bone/Pain products</b>	<b>392</b>	<b>376</b>	<b>4</b>
<b>Infectious Diseases, Transplantation &amp; Immunology (IDTI)</b>			
<i>Neoral/Sandimmun</i>	233	235	-1
Other	110	82	34
<b>Total strategic franchise products</b>	<b>343</b>	<b>317</b>	<b>8</b>
<b>Mature products</b>	<b>82</b>	<b>66</b>	<b>24</b>
<b>Total IDTI products</b>	<b>425</b>	<b>383</b>	<b>11</b>
<b>Total strategic franchise products</b>	<b>4 870</b>	<b>4 435</b>	<b>10</b>
<b>Total mature products</b>	<b>1 195</b>	<b>1 264</b>	<b>-5</b>
<b>Total division net sales</b>	<b>6 065</b>	<b>5 699</b>	<b>6</b>

---

(1) Acquired on April 20, 2006, through the purchase of Chiron

## Net sales by region (unaudited)

## First half

	H1 2007	H1 2006	% change		H1 2007	H1 2006
	USD m	USD m	USD	local currencies	% of total	% of total
<b>Pharmaceuticals</b>						
US	4 744	4 510	5	5	40	42
Rest of world	7 244	6 241	16	11	60	58
<b>Total</b>	<b>11 988</b>	<b>10 751</b>	<b>12</b>	<b>9</b>	<b>100</b>	<b>100</b>
<b>Vaccines and Diagnostics</b>						
US	146	46	217	217	30	36
Rest of world	336	81	315	298	70	64
<b>Total</b>	<b>482</b>	<b>127</b>	<b>280</b>	<b>267</b>	<b>100</b>	<b>100</b>
<b>Sandoz</b>						
US	953	749	27	27	28	26
Rest of world	2 462	2 132	15	8	72	74
<b>Total</b>	<b>3 415</b>	<b>2 881</b>	<b>19</b>	<b>13</b>	<b>100</b>	<b>100</b>
<b>Consumer Health<sup>(1)</sup></b>						
US	1 799	1 761	2	2	44	47
Rest of world	2 257	1 963	15	9	56	53
<b>Total</b>	<b>4 056</b>	<b>3 724</b>	<b>9</b>	<b>6</b>	<b>100</b>	<b>100</b>
<b>Group<sup>(1)</sup></b>						
US	7 642	7 066	8	8	38	40
Rest of world	12 299	10 417	18	12	62	60
<b>Total</b>	<b>19 941</b>	<b>17 483</b>	<b>14</b>	<b>11</b>	<b>100</b>	<b>100</b>

(1) Includes both Consumer Health Division continuing and discontinuing operations

## Net sales by region (unaudited)

## Second quarter

	Q2 2007	Q2 2006	% change		Q2 2007	Q2 2006
	USD m	USD m	USD	local currencies	% of total	% of total
<b>Pharmaceuticals</b>						
US	2 281	2 416	-6	-6	38	42
Rest of world	3 784	3 283	15	10	62	58
<b>Total</b>	<b>6 065</b>	<b>5 699</b>	<b>6</b>	<b>4</b>	<b>100</b>	<b>100</b>
<b>Vaccines and Diagnostics</b>						
US	74	46	61	61	29	36
Rest of world	177	81	119	107	71	64
<b>Total</b>	<b>251</b>	<b>127</b>	<b>98</b>	<b>90</b>	<b>100</b>	<b>100</b>
<b>Sandoz</b>						
US	479	378	27	26	28	26
Rest of world	1 240	1 072	16	8	72	74
<b>Total</b>	<b>1 719</b>	<b>1 450</b>	<b>19</b>	<b>13</b>	<b>100</b>	<b>100</b>
<b>Consumer Health<sup>(1)</sup></b>						
US	908	889	2	2	44	47
Rest of world	1 179	1 017	16	10	56	53
<b>Total</b>	<b>2 087</b>	<b>1 906</b>	<b>9</b>	<b>6</b>	<b>100</b>	<b>100</b>
<b>Group<sup>(1)</sup></b>						
US	3 742	3 729	0	0	37	41
Rest of world	6 380	5 453	17	11	63	59
<b>Total</b>	<b>10 122</b>	<b>9 182</b>	<b>10</b>	<b>7</b>	<b>100</b>	<b>100</b>

(1) Includes both Consumer Health Division continuing and discontinuing operations

## Quarterly analysis

Key figures by quarter<sup>(1)</sup>

	Q2 2007 USD m	Q1 2007 USD m	Change USD m	%
Net sales	10 122	9 819	303	3
Operating income	2 216	2 453	-237	-10
Financial income	90	87	3	3
Interest expense	-57	-53	-4	8
Taxes	-328	-413	85	-21
Net income	2 016	2 171	-155	-7

(1) Includes both Consumer Health Division continuing and discontinuing operations

Net sales by region<sup>(1)</sup>

	Q2 2007 USD m	Q1 2007 USD m	Change USD m	%
US	3 742	3 900	-158	-4
Europe	4 010	3 808	202	5
Rest of world	2 370	2 111	259	12
Total	10 122	9 819	303	3

(1) Includes both Consumer Health Division continuing and discontinuing operations

## Net sales by division

	Q2 2007 USD m	Q1 2007 USD m	Change USD m	%
Pharmaceuticals	6 065	5 923	142	2
Vaccines and Diagnostics	251	231	20	9
Sandoz	1 719	1 696	23	1
Consumer Health continuing operations	1 365	1 278	87	7
Net sales from continuing operations	9 400	9 128	272	3
Consumer Health discontinuing operations	722	691	31	4

<b>Total</b>	<b>10 122</b>	9 819	303	3
--------------	---------------	-------	-----	---

**Operating income by division**

	<b>Q2 2007</b> USD m	<b>Q1 2007</b> USD m	<b>Change</b> USD m	<b>%</b>
<b>Pharmaceuticals</b>	<b>1 767</b>	1 853	-86	-5
<b>Vaccines and Diagnostics</b>	<b>-20</b>	27	-47	-174
<b>Sandoz</b>	<b>243</b>	318	-75	-24
<b>Consumer Health continuing operations</b>	<b>243</b>	240	3	1
Corporate income & expense, net	<b>-136</b>	-103	-33	32
<b>Operating income from continuing operations</b>	<b>2 097</b>	2 335	-238	-10
Consumer Health discontinuing operations	<b>119</b>	118	1	1
<b>Total</b>	<b>2 216</b>	2 453	-237	-10

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Novartis AG**

Date: July 17, 2007

By: /s/ MALCOLM B. CHEETHAM

Name: Malcolm B. Cheetham  
Title: Head Group Financial  
Reporting and Accounting